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Introduction
The multistage model of carcinogenesis describes the pro-
gression of normal cells to initiated and preneoplastic cells,
and finally to malignant and metastatic disease. Inherited
genotypes are known to play a prominent role in the initia-
tion of breast tumors. For example, it is well known that
germline mutations in BRCA1 can initiate breast tumorige-
nesis [1]. However, inherited genotypes may also act at a
variety of other steps in the multistage process of breast
carcinogenesis. These genotypes may not only affect
disease susceptibility, but also disease outcome.
Figure 1 presents a number of classes of genes acting in
multistage carcinogenesis. In this presentation, G denotes
genotypes at a single locus. Subscripts to G are used to
distinguish different classes of genes that may act at dif-
ferent points in the development and progression of a
tumor. As described in detail below, GE are involved in
metabolic pathways that determine propensity to be
exposed to breast carcinogens. GP are involved in the
metabolism of chemopreventive agents. These genes can
determine the degree to which an individual’s cancer risk
may be modified, or the degree to which an individual will
suffer adverse side effects from exposure to the agent. GD
include genes that are directly involved in the etiology of a
tumor. These genes are typically involved in studies
addressing disease susceptibility, and generally represent
those genes considered in evaluating cancer risk. GT are
genes involved in the determination of drug dissemination
and metabolism. Thus, GT determine in part the efficacy or
toxicity of a drug. GO are determinants of a tumor’s natural
history, as it progresses from a more benign to a more
advanced stage. Each of these classes of genes will be
defined in this commentary, with examples that illustrate
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how inherited genotype information can be used to better
understand the multistep carcinogenesis process and
improve cancer detection, prevention, and treatment. It is
important to note that the genes that fall into each of these
classes are not mutually exclusive: genes involved in the
metabolism of xenobiotic compounds could play the role
of any of these multistep events, while other genes may
play a greater role in one step than others. Implicit in this
model is the role that inherited genotypes may play in
cancer prevention by better defining modifiable aspects of
carcinogenesis.
Inherited genetic determinants of
carcinogenic exposures: GE
GE include genes involved in metabolic pathways that
determine propensity to be exposed to endogenous or
exogenous carcinogens. For example, a number of investi-
gators have related GE involved in neurotransmitter metab-
olism (e.g. DRD4, SLCA3, and 5-HTTLPR) with propensity
to smoke, smoking initiation at an early age, ability to stop
smoking, and nicotine dependence [2–5]. Similarly, a
number of investigators have related GE of steroid hormone
metabolism to interindividual variability in hormone-related
risk factors. Among the most widely studied of these genes
is CYP17, a member of the cytochrome P450 multigene
family, which is responsible for conversion of progesterone
to androstenedione in the biosynthesis of estrone. A
number of authors have evaluated the relationship of a 5′-
untranslated region polymorphism at CYP17 with age at
menarche [6–9], use of hormone replacement therapy [6],
or circulating hormone levels [9]. The relationship of
CYP17 genotype with age at menarche was not consistent
in all studies, and there have not been independent confir-
mations of the reported associations of hormone replace-
ment therapy use or circulating hormone levels. These
examples point to the possibility that GE may influence
propensity to be exposed to ‘traditional’ risk factors, may
elucidate biologically relevant prevention pathways, and
may identify individuals who should be targeted for expo-
sure modification or other preventive strategies.
Inherited genetic determinants of
chemoprevention response and toxicity: GP
GP include genes that permit the prediction of an individu-
al’s response to a chemopreventive agent, and may define
those individuals who could have increased toxicities
when exposed to these agents. Few examples of GP in
cancer chemoprevention exist. Tamoxifen, an antiestro-
genic drug used for the prevention of breast cancer, is
metabolized to the antiestrogenic 4-hydroxytamoxifen
(4-OHT) by SULT1A1 and to N-desmethyl tamoxifen by
CYP3A4 [10,11]. The N-desmethyl form is quantitatively
the major antiestrogenic metabolite, although the 4-OHT
form is 100-fold more antiestrogenic than the N-desmethyl
form. Therefore, the genes SULT1A1 and  CYP3A4 are
candidate GP, because the variants that affect the metab-
olism of tamoxifen to 4-OHT or N-desmethyl tamoxifen
indicate which individuals have either an optimal chemo-
preventive response or the potential for increased toxicity
following tamoxifen administration. Although SULT1A1
and CYP3A4 encode key enzymes in the metabolism of
tamoxifen, a number of other genes, including CYP2D6
and CYP2C9, are also involved in tamoxifen metabolism.
Furthermore, sulfate conjugation of 4-OHT by SULT1A1
can reduce the antiestrogenic properties of tamoxifen
metabolites. As with most complex metabolic systems,
numerous GP with multiple functions need to be consid-
ered to fully evaluate the pharmacogenetics of cancer
chemoprevention. Knowledge of GP may dictate that the
protective or toxic effects of an agent occur only in a
subset of individuals with a specific genotype.
Inherited genetic determinants of cancer
etiology: GD
In the model presented in Figure 1, GD link the relationship
between exposure and disease. This relationship can be
made independently of any other information about the
complex pathways involved in the process of carcinogene-
sis. Alternatively, this relationship can be made consider-
ing other biomarkers, such as those of exposure, internal
dose, (biologically) effective dose, or early effect, as
described in detail by Schulte and Perera [12]. The
Figure 1
Role of inherited susceptibility genotypes along the continuum of
multistage carcinogenesis to determine exposure (GE), disease risk
(GD), efficacy and response to chemoprevention (GP) or treatment
(GT), and natural history or disease outcome (GO). B denotes
biomarkers of exposure (Bexposure), internal dose (Binternal dose), effective
dose (Beffective dose), or early effect (Bearly effect) as defined by Schulte
and Perera [12].consideration of GD, intermediate biomarkers, and expo-
sures in association studies of disease has been referred
to as a ‘level crossing’ model [13].
Two GD subclasses have been the focus of much
research in the genetic etiology of breast cancer, and are
usually referred to as ‘high penetrance’ and ‘low pene-
trance’. There are a few high penetrance GD with allelic
variants (mutations) that confer a high degree of risk to the
individual, but occur infrequently in the general population.
Because these alleles are rare, the proportion of breast
cancer in the population that may be explained by these
genotypes is low. Because of the large magnitude of
effects these genotypes have on cancer risk, one hallmark
of high penetrance GD is the creation of a Mendelian
(usually autosomal dominant) pattern of cancer in families.
Only a small proportion (perhaps 5%) of breast cancer
can be attributed to inherited single gene mutations in
genes such as BRCA1, BRCA2, TP53, PTEN, and
STK11. Even in women who have inherited these muta-
tions, the penetrance of breast cancer may be modified by
other genes or exposures [14,15].
Low penetrance GD confer a small to moderate degree
of breast cancer risk to the individual. It is expected that
disease-associated alleles in these genes may be rela-
tively common, and thus may explain a relatively larger
proportion of cancer in the population. The search for
low penetrance GD generally relies on knowledge about
biochemical or physiological pathways involved in breast
carcinogenesis (i.e. ‘candidate gene’ studies). A number
of study designs are available to evaluate the role of GD
in breast cancer etiology, including traditional epidemio-
logic methods of case-case studies, case-control
studies, and cohort studies (reviewed by Thomas [16],
Caporaso [17], and Langholz [18]), and family-based
studies [19,20]. There are numerous examples of path-
ways that define candidate low penetrance GD in breast
cancer etiology. These include genes involved in the
metabolism of environmental carcinogens (e.g. CYP2D6,
CYP2C19, GSTM1, GSTP1, GSTT1, NAT1,  NAT2),
those involved in steroid hormone metabolism (e.g.
CYP17, CYP19, CYP1A1, CYP1A2, CYP3A4, COMT),
and others, including those involved in DNA damage
recognition and repair. Despite the many potential candi-
date genes, few consistent associations between these
genes and breast cancer risk have been identified. Many
of these studies have been undertaken in small sample
sets, and there have rarely been confirmatory analyses
using independent study samples. Therefore, it is difficult
to assess whether consistent and strong associations
exist. While many of these genes may play a role in
breast cancer etiology, there remains relatively little infor-
mation about which low penetrance GD are involved, and
in which populations these effects of GD on breast
cancer risk will be observed.
Inherited genetic determinants of treatment
response and toxicity: GT
GT are conceptually similar to GP because they are
involved in the dissemination and metabolism of a pharma-
cological agent, and thereby contribute to an agent’s effi-
cacy and toxicity. Therefore, GT may influence the
structure or amount of these agents, influence drug phar-
macodynamics and metabolism, and permit the prediction
of interindividual variability in the response to drug treat-
ment, or its toxicity. A paradigm for the role of inherited
genotype in dictating treatment regimen is the use of
drugs that contain thiopurine, which are metabolized by
thiopurine methyltransferase (TPMT) [21]. Approximately
one in 300 US Caucasians carry a TPMT genotype that
results in the inability to methylate thiopurine drugs, which
can cause potentially fatal myelosuppression [22]. There-
fore, acquiring knowledge of an individual’s TPMT geno-
type and phenotype has become part of standard clinical
practice with treatments involving thiopurines [22,23].
Other classes of enzymes, including dihydropyrimidine
dehydrogenase, aldehyde dehydrogenases, glutathione S-
transferases, uridine diphosphate glucuronosyl-trans-
ferases, and cytochromes P450, may also have
pharmacogenetic significance in determining cancer
chemotherapy regimens [24]. These include improved
determination of type, timing, and dose of treatment tai-
lored to an individual’s GT.
Inherited genetic determinants of clinical
outcome: GO
The natural history of cancer progression may be influ-
enced by GO, which affect the tumor histopathology,
including the stage or grade of disease, the rate of
disease progression, or the propensity for metastasis. In
contrast to the study of inherited genetic variants and clini-
cal outcome, there is a large body of research that evalu-
ates histopathological measures or somatic genetic
mutations (e.g. loss or amplification of specific genes in
tumors; estrogen or progesterone receptor positivity) with
the natural history of cancer progression, and therefore
clinical prognosis. A paradigm for this type of marker is
that of HER2 amplification/overexpression in breast
cancer prognosis [25].
Inherited (germline) mutations in candidate GO may be
associated with disease prognosis if they are involved in
metabolic events that lead to tumorigenesis and progres-
sion. These events include regulation of somatic DNA
damage or repair directly (via the metabolism of com-
pounds that induce DNA damage) and by metabolism of
steroid hormones that influence tumor growth. Therefore,
some candidate GD may also be candidate GO. Further-
more, because some genes may affect both natural history
(i.e. GO) and treatment response (i.e. GT), it is also impor-
tant to evaluate these potentially separate or complemen-
tary effects.
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The ability to identify consistent associations between
inherited genotype and breast cancer requires that appro-
priate epidemiological and clinical studies be designed
specifically to address these issues. Most studies that
report the effects of genotype on tumor traits have not
been specifically designed to study these relationships,
but instead were reported in the context of case-control or
cohort studies. Often, the criteria for determining the inclu-
sion or exclusion of a case in a study are not adequately
defined, or are sometimes inappropriately collected for the
evaluation of natural history and prognosis. Studies are
often not specifically designed to have adequate statistical
power for the evaluation of these questions. In particular,
prospective follow-up of a well-defined cohort of patients
may be inadequate or incomplete. Evidence for the limita-
tion of sample size of many studies is given by the many
reports in which genotype was inferred to have no effect
when the associated P values fell in the range 0.05–0.10,
even though moderately large effect sizes were observed.
An important implication for chemoprevention trials is that
sample size requirements will be dictated not only by the
proposed reduction in cancer incidence in the treatment
arm, but also by the proportion of individuals in the popula-
tion who carry a particular variant genotype. These consid-
erations could make the design and execution of
chemopreventive studies considerably more difficult to
achieve than if GP were not considered.
Inconsistent inferences between studies are also
common. A number of factors can be identified as con-
tributing to these inconsistencies. A major concern is
limited statistical power to identify or replicate associa-
tions in some studies. Differences in the definition and dis-
tribution of tumor stages and grades may affect study
inferences. For example, differences in cancer screening
practices at the time of case ascertainment may result in
inconsistencies among studies. When this information is
unavailable or not described, results appropriate for each
population but that differ across populations may be inter-
preted as inconsistent findings. Studies that evaluate
inherited genotype and tumor characteristics, natural
history, or prognosis could benefit by reporting the distrib-
ution of screening practices and the stages or grades of
tumors studied. Similarly, ethnic or exposure differences
among study populations could induce apparent inconsis-
tencies. These differences may reflect real differences
across populations, and not a failure of the methodology.
Finally, multiple etiological factors should be considered
simultaneously to determine whether inherited genotype
provides additional information about natural history, prog-
nosis, or treatment response that is independent of other
traits including histopathological characteristics. Inherited
genotypes will only have value in predicting outcome if
they provide readily accessible information beyond that
routinely used and collected from these patients.
Advances in these areas will improve our understanding of
the multistep carcinogenesis process, and will potentially
improve cancer detection, prevention, and treatment.
References
1. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of
breast and ovarian cancer. Hum Mol Genet 2001, 10:705-713.
2. Lerman C, Shields PG, Audrain J, Main D, Cobb B, Boyd NR,
Caporaso N: The role of the serotonin transporter gene in cig-
arette smoking.  Cancer Epidemiol Biomarkers Prev 1998,  7:
253-255.
3. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S,
Sirota LA, Marcus SE, Greenberg BD, Lucas FR 4th, Benjamin J,
Murphy DL, Hamer DH: A genetic association for cigarette
smoking behavior. Health Psychol 1999, 18:7-13.
4. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lock-
shin B, Boyd NR, Shields PG: Evidence suggesting the role of
specific genetic factors in cigarette smoking. Health Psychol
1999, 18:14-20.
5. Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields
PG: Interacting effects of the serotonin transporter gene and
neuroticism in smoking practices and nicotine dependence.
Mol Psychiatry 2000, 5:189-192.
6. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson
BE: A polymorphism in the CYP17 gene increases the risk of
breast cancer. Cancer Res 1997, 57:1063-1065.
7. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N,
Wolff MS: CYP17 genotype and breast cancer risk. Cancer
Epidemiol Biomarkers Prev 1998, 7:941-944.
8. Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ,
Comstock GW, Bell DA: Association between CYP17 polymor-
phisms and the development of breast cancer. Cancer Epi-
demiol Biomarkers Prev 1998, 7:945-949.
9. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett
WC, Speizer FE, Kelsey KT, Hunter DJ: The relationship
between a polymorphism in CYP17 with plasma hormone
levels and breast cancer. Cancer Res 1999, 59:1015-1020.
10. Dehal SS, Kupfer D: CYP2D6 catalyzes tamoxifen 4-hydroxyla-
tion in human liver. Cancer Res 1997, 57:3402-3406.
11. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C and Berthou F:
Identification of the cytochrome P450 IIIA family as the
enzymes involved in the N-demethylation of tamoxifen in
human liver microsomes. Biochem Pharmacol 1991, 41:1911-
1919.
12. Schulte PA, Perera FP (Ed): Molecular Epidemiology: Principles
and Practices. San Diego: Academic Press; 1993.
13. Sing CF, Boerwinkle E, Turner ST: Genetics of primary hyper-
tension. Clin Exp Hypertens A 1986, 8:623-651.
14. Rebbeck TR, Kantoff PA, Krithivas K, Godwin AK, Daly MB, Narod
SA, Garber JE, Weber BL, Brown M: Modification of BRCA1-
associated breast cancer penetrance by androgen receptor
CAG repeat length variants.  Am J Human Genet 1999,  64:
1371-1377.
15. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen S,
Godwin AK, Daly MB, Narod SA, Brunet J-S, Vesprini D, Garber
JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1-
and BRCA2-associated breast cancer risk by AIB1 genotype
and reproductive history.  Cancer Research 2001,  61:5420-
5424.
16. Thomas DC: Design of gene characterization studies: an
overview. J Natl Cancer Inst Monogr 1999, 26:17-23.
17. Caporaso N, Rothman N, Wacholder S: Case-control studies of
common alleles and environmental factors. J Natl Cancer Inst
Mongr 1999, 26:25-30.
18. Langholz B, Rothman N, Wacholder S, Thomas DC: Cohort
studies for characterizing measured genes. J Natl Cancer Inst
Monogr 1999, 26:39-42.
19. Gauderman WJ, Witte JS, Thomas DC: Family-based associa-
tion studies. J Natl Cancer Inst Monogr 1999, 26:31-37.
20. Goldstein AM, Andrieu N: Detection of interaction involving
identified genes: available study designs. J Natl Cancer Inst
Monogr 1999, 26:49-54.
Breast Cancer Research    Vol 4 No 3 Rebbeck21. Krynetski EV, Evans WE: Genetic polymorphism of thiopurine
S-methyltransferase: molecular mechanisms and clinical
importance. Pharmacology 2000, 61:136-146.
22. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T,
Schuetz JD, Relling MV, Evans WE: Genetic polymorphism of
thiopurine S-methyltransferase: clinical importance and mol-
ecular mechanisms. Pharmacogenetics 1996, 6:279-290.
23. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J,
Park-Hah JO, Iven H, Schmiegelow K, Branum E, O’Brien J, Wein-
shilboum R: Human thiopurine methyltransferase pharmaco-
genetics: gene sequence polymorphisms.  Clin Pharmacol
Ther 1997, 62:60-73.
24. Iyer L, Ratain MJ: Pharmacogenetics and cancer chemother-
apy. Eur J Cancer 1998, 34:1493-1499.
25. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A: HER2 as a
prognostic factor in breast cancer. Oncology 2001, 61(suppl
2):67-72.
Available online http://breast-cancer-research.com/content/4/3/085